Eli Lilly Beats Q3 Revenue Forecasts on Expanded Incretin Drug Manufacturing Capacity
Eli Lilly topped third-quarter expectations with $11.45 billion in revenue as expanded manufacturing boosted supply of Mounjaro and Zepbound.
Manufacturing Expansion Pays Off
Eli Lilly reported third-quarter revenue of $11.45 billion, surpassing Wall Street expectations of $10.9 billion. The strong results were fueled by surging availability of Mounjaro and Zepbound as multi-billion-dollar investments in domestic and European manufacturing facilities reached commercial-scale output.
Incretin Market Leadership
Combined sales for tirzepatide treatments topped $4.3 billion during the quarter. Prescription volume increased over 80% sequentially as retail pharmacy fulfillment bottlenecks eased, allowing Eli Lilly to gain market share in the rapidly expanding metabolic disease and chronic weight management sectors.